Synergistic anticancer effects of Bufalin and sorafenib by regulating apoptosis associated proteins

Haiyong Wang, Chenyue Zhang, Huiying Chi, Zhiqiang Meng

    Research output: Contribution to journalArticle

    2 Scopus citations

    Abstract

    As one of the most recognized and well-known drugs for hepatocellular carcinoma (HCC), the antitumor effect of sorafenib against HCC remains to be improved. Bufalin has displayed an antitumor effect in HCC; however, whether the enhanced antitumor effect may be generated with their combined treatment remains unclear. Therefore, in the present study, their combined effects on HCC proliferation and apoptosis were investigated. It was revealed that either bufalin or sorafenib suppressed PLC/PRF/5 and SMMC-7721 cell proliferation in a concentration-dependent manner following incubation for 24 h, and the inhibitory effect was augmented with their combined treatment. The synergistic effect peaked in HCC cells treated with 20 nM bufalin and 10 μM sorafenib. In addition, cell cycle and terminal deoxynucleotidyl transferase dUTP nick-end labelling assays revealed that bufalin also enhanced sorafenib-induced apoptosis. Colony formation assay demonstrated that combined treatment significantly suppressed HCC proliferation compared with treatment with either of them alone. Furthermore, B-cell lymphoma 2-associated X protein, caspase 7 and poly-(adenosine diphosphate-ribose) polymerase were upregulated in HCC cells with combined treatment. Taken together, the results of the present study revealed that the treatment of sorafenib combined with bufalin synergistically suppressed HCC proliferation and induced apoptosis. Therefore, bufalin combined with sorafenib may be a favorable treatment strategy for patients with HCC.

    Original languageEnglish (US)
    Pages (from-to)8101-8110
    Number of pages10
    JournalMolecular medicine reports
    Volume17
    Issue number6
    DOIs
    StatePublished - Jun 2018

    Keywords

    • Apoptosis
    • Bufalin
    • Hepatocellular carcinoma
    • Sorafenib

    ASJC Scopus subject areas

    • Biochemistry
    • Molecular Medicine
    • Molecular Biology
    • Genetics
    • Oncology
    • Cancer Research

    Fingerprint Dive into the research topics of 'Synergistic anticancer effects of Bufalin and sorafenib by regulating apoptosis associated proteins'. Together they form a unique fingerprint.

  • Cite this